Delafloxacin Meglumine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 450 mg
Reference Brands: Baxdela (USA/EU)
Category:
Antibiotics
Delafloxacin meglumine is available in Tablets
and strengths such as 450 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Delafloxacin meglumine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Delafloxacin meglumine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Delafloxacin, sold under the brand name Baxdela, is a broad-spectrum fluoroquinolone antibiotic used for the treatment of acute bacterial infections. It is primarily indicated for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Additionally, delafloxacin is approved for the treatment of community-acquired bacterial pneumonia (CABP) in adults caused by designated susceptible pathogens.
Delafloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair, thereby preventing bacterial growth and proliferation. It is available in both intravenous and oral formulations, allowing flexible treatment options and seamless transition from hospital to outpatient care. The medication is formulated as delafloxacin meglumine for IV administration and as delafloxacin tablets for oral use, ensuring optimal bioavailability and efficacy.
Developed and commercialized under the brand name Baxdela, delafloxacin is manufactured in compliance with international regulatory standards, including US FDA and EU GMP guidelines. It offers healthcare providers a potent and versatile option for managing complicated bacterial infections in adult patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing